Welcome to our dedicated page for Medicus Pharma SEC filings (Ticker: MDCXW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medicus Pharma Ltd. SEC filings document material-event reporting for a clinical-stage life sciences and biotechnology company incorporated in Ontario. The filings identify the company's one-segment operating model and record capital-structure activity involving common shares, shelf registration statements, at-the-market offering arrangements and a standby equity purchase agreement.
Recent Form 8-K disclosures also cover unregistered equity sales, debenture financing with subsidiary guaranties, debt repayment mechanics, amendments to equity distribution agreements and listing-compliance notices. These filings frame the company's financing arrangements, governance obligations, securities registration activity and exchange-status disclosures.
Medicus Pharma Ltd. held its 2026 Annual General and Special Meeting of Shareholders on June 3, 2026. Shareholders ratified the appointment of KPMG LLP as independent auditor for the 2026 fiscal year, with 28,308,860 votes for and 756,378 votes withheld.
All nine director nominees were elected, each receiving about 15.1 million votes for and 13.5 million broker non-votes. Shareholders also approved a special resolution authorizing the board to implement a consolidation of the company’s common shares at a ratio of up to 50 pre-consolidation shares for each post-consolidation share, if the board determines such a step is necessary or desirable.
Medicus Pharma Ltd. Chief Operating Officer Andrew Alasdair Smith received a grant of stock options covering 200,000 common shares on June 3, 2026. The options have an exercise price of $0.36 per share, vest quarterly in four equal installments over one year, and expire on June 3, 2031. Following this grant, he holds 200,000 options directly.
Medicus Pharma Ltd. director Cathy McMorris Rodgers received a grant of stock options covering 50,000 common shares. The options have an exercise price of $0.36 per share and expire on June 3, 2031. According to the footnote, the award vests quarterly in four equal installments over one year, meaning the director earns 12,500 options every quarter until fully vested. Following this grant, she holds 50,000 stock options directly, providing equity-based compensation linked to the company’s future share performance.
Medicus Pharma Ltd. director Ajay Raju received a grant of stock options covering 50,000 common shares. The options have an exercise price of $0.36 per share and were granted as a compensation award at no upfront cost. They are scheduled to vest quarterly in four equal installments over one year, giving Raju the right, once vested, to buy Medicus Pharma common shares at the fixed exercise price until the options expire in 2031.
Medicus Pharma Ltd. reported that Chief Medical Officer Mehmud Faisal received a grant of stock options covering 250,000 Common Shares. The options carry an exercise price of $0.36 per share and expire on June 3, 2031. According to the disclosure, the options were granted on June 3, 2026 and are scheduled to vest quarterly in four equal installments over one year. Following this award, Faisal holds 250,000 stock options directly.
Medicus Pharma Ltd. director May Sara R. received a grant of stock options covering 50,000 common shares. The options have an exercise price of $0.36 per share and expire on June 3, 2031. Following this grant, she holds options for 50,000 shares directly.
According to the terms, the option grant was made on June 3, 2026 and is scheduled to vest quarterly in four equal installments over one year. This is a compensation-related award, not an open-market purchase or sale of shares.
Medicus Pharma Ltd. director Patrick J. Mahaffy reported receiving a stock option grant for 50,000 underlying common shares. The option carries an exercise price of $0.36 per share, was granted on June 3, 2026, and is scheduled to vest quarterly in four equal installments over one year. The option expires on June 3, 2031, and represents a compensation-related award rather than an open-market share purchase or sale.
Medicus Pharma Ltd. director Larry Kaiser received a grant of stock options, giving him the right to acquire 50,000 common shares. The options have an exercise price of $0.36 per share and expire on June 3, 2031. Following this grant, he holds stock options for 50,000 shares. According to the grant terms, the options vest quarterly in four equal installments over one year, meaning the award becomes exercisable gradually rather than all at once.
Medicus Pharma Ltd. director Barry Fishman received a grant of stock options representing 50,000 common shares. The options have an exercise price of $0.36 per share and expire on June 3, 2031. They were granted on June 3, 2026 and are scheduled to vest quarterly in four equal installments over one year. Following this grant, Fishman holds 50,000 derivative securities directly.
Medicus Pharma Ltd. director Robert J. Ciaruffoli received a grant of stock options covering 50,000 common shares. The options have an exercise price of $0.36 per share, were granted on June 3, 2026, and are scheduled to vest quarterly in four equal installments over one year.
These options expire on June 3, 2031, and represent 50,000 derivative securities held by Ciaruffoli following this compensation-related award. The filing reports no open-market purchases or sales of Medicus Pharma common shares.